Peanut Allergy 2019

As the draft report notes, “the quality of life outcomes for the phase 3 trials have not yet been published. It is [therefore] challenging to fully evaluate the impact of these therapies without placebo-controlled assessments of the change in quality of life.” Given the reality of such limited data – particularly about patient perspectives and quality – we believe it is too early for ICER to conduct this assessment.

Continue Reading

Asthma 2019

We appreciate the opportunity to provide our comments on the September 24th draft report, “Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price…

Continue Reading
Close Menu